Granted Patent
B2
US 12,403,136 · App. 17/627,946 · Granted Sep 2, 2025
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
Inventors:
Alan Silcock (Cambridge, GB); Benjamin Whalley (Cambridge, GB); Royston Gray (Cambridge, GB); Hannah Straker (Cambridge, GB); Karen Tse (Cambridge, GB); Alexander Cobb (London, GB); Laura Bryant (Leigh-on-Sea, GB)
Assignee:
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
A61K31/47A61K31/05A61K31/055A61K31/353A61K45/06A61P25/08C07C37/16C07C39/23C07C41/06C07D215/06C07D215/14C07D215/20C07D215/48C07D311/58C07D311/64
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention
Claims (17)
1. A compound of the general Formula I or a salt thereof
where X is either CH 2 ; O; NBoc; NFMoc; NZ; NTs; NAc; NC (O)iPr; NBz or NH and Y is either H or OH.
2. A compound of general Formula II or a salt thereof
where X is either CH 2 ; O; NBoc; NFMoc; NZ; NTs; NAc; NC (O) iPr; NBz or NH and Y is either H or OH.
3. A pharmaceutical composition comprising a compound of claim 1 or salt thereof.
4. A pharmaceutical composition as claimed in claim 3 , wherein the pharmaceutical composition is selected from a tablet, a capsule, a granule, a powder for inhalation, a sprinkle, an oral solution and a suspension.
5. A pharmaceutical composition as claimed in claim 3 , wherein the composition additionally comprises one or more of: an excipient selected among a carrier, an oil, a disintegrant, a lubricant, a stabilizer, a flavouring agent, an antioxidant, a diluent and another pharmaceutically effective compound.
6. A method of treating epilepsy in a mammal in need thereof comprising administering a pharmaceutical preparation comprising a compound of claim 1 or salt thereof.
7. A process for the production of a compound of general Formula I comprising reacting a resorcinol unit of Structure 1a-j via a Friedel-Crafts 1,4-addition to produce compounds of Structures 2a to 2j or 3a to 3j followed by subsequent steps to produce the compounds of general Formula I via intermediates.
8. A compound selected from any one of:
wherein R 1 is H, and
wherein X is selected from any one of CH 2 , O, NBoc, NFmoc, NZ, NTs, NAc, NC(O)iPr and NBz.
9. A pharmaceutical composition comprising a compound of claim 2 or salt thereof.
10. A pharmaceutical composition as claimed in claim 9 , wherein the pharmaceutical composition is selected from a tablet, a capsule, a granule, a powder for inhalation, a sprinkle, an oral solution and a suspension.
11. A pharmaceutical composition as claimed in claim 9 , wherein the composition additionally comprises one or more of: an excipient selected among a carrier, an oil, a disintegrant, a lubricant, a stabilizer, a flavouring agent, an antioxidant, a diluent and another pharmaceutically effective compound.
12. A method of treating epilepsy in a mammal in need thereof comprising administering a pharmaceutical preparation comprising a compound of claim 2 or a salt thereof.
13. A process for the production of a compound of general Formula II comprising reacting a resorcinol unit of Structure 1a-j via a Friedel-Crafts 1,4-addition to produce compounds of Structures 2a to 2j or 3a to 3j followed by subsequent steps to produce the compounds of general Formula II via intermediates.
Assignments (3)
CHANGE OF NAME
Recorded May 19, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071152/0921 →
SECURITY AGREEMENT
Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 2, 2022
From: SILCOCK, ALAN; WHALLEY, BENJAMIN; GRAY, ROYSTON; STRAKER, HANNAH; TSE, KAREN; COBB, ALEXANDER; BRYANT, LAURA
To: GW RESEARCH LIMITED
Reel/Frame 059786/0286 →
Priority Claims (1)
GB 1910389
· Jul 19, 2019
· national
Continuity (1)
References Cited (261)
US 8632825B2
· Velasco Diez et al.
· 2014
[cited by applicant]
US 8790719B2
· Parolaro et al.
· 2014
[cited by applicant]
US 9017737B2
· Kikuchi et al.
· 2015
[cited by applicant]
US 9125859B2
· Whalley et al.
· 2015
[cited by applicant]
US 9474726B2
· Guy et al.
· 2016
[cited by applicant]
US 9675654B2
· Parolaro et al.
· 2017
[cited by applicant]
US 9949936B2
· Guy et al.
· 2018
[cited by applicant]
US 9949937B2
· Guy et al.
· 2018
[cited by applicant]
US 9956183B2
· Guy et al.
· 2018
[cited by applicant]
US 9956184B2
· Guy et al.
· 2018
[cited by applicant]
US 9956185B2
· Guy et al.
· 2018
[cited by applicant]
US 9956186B2
· Guy et al.
· 2018
[cited by applicant]
US 9962341B2
· Stott et al.
· 2018
[cited by applicant]
US 20150274623A1
· Makriyannis et al.
· 2015
[cited by applicant]
US 20150359756A1
· Guy et al.
· 2015
[cited by applicant]
US 20170008868A1
· Dialer et al.
· 2017
[cited by applicant]
US 20170239193A1
· Guy et al.
· 2017
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20180228751A1
· Stott et al.
· 2018
[cited by applicant]
US 20190167583A1
· Shah
· 2019
[cited by applicant]
US 20190314296A1
· Wright et al.
· 2019
[cited by applicant]
US 20190321307A1
· Guy et al.
· 2019
[cited by applicant]
US 20190365667A1
· Wright et al.
· 2019
[cited by applicant]
US 20200138738A1
· Guy et al.
· 2020
[cited by applicant]
US 20200179303A1
· Guy et al.
· 2020
[cited by applicant]
US 20200206153A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200237683A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200297656A1
· Guy et al.
· 2020
[cited by applicant]
US 20200352878A1
· Guy et al.
· 2020
[cited by applicant]
US 20210015789A1
· Guy et al.
· 2021
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210059949A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059960A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210069333A1
· Velasco Diez et al.
· 2021
[cited by applicant]
US 20210169824A1
· Guy et al.
· 2021
[cited by applicant]
US 20210290565A1
· Guy et al.
· 2021
[cited by applicant]
US 20210330636A1
· Guy et al.
· 2021
[cited by applicant]
US 20210401771A1
· Guy et al.
· 2021
[cited by applicant]
US 20220000800A1
· Guy et al.
· 2022
[cited by applicant]
US 20220008355A1
· Guy et al.
· 2022
[cited by applicant]
US 20220016048A1
· Guy et al.
· 2022
[cited by applicant]
US 20220023232A1
· Guy et al.
· 2022
[cited by applicant]
US 20220040155A1
· Guy et al.
· 2022
[cited by applicant]
US 20220062197A1
· Stott et al.
· 2022
[cited by applicant]
US 20220062211A1
· Stott et al.
· 2022
[cited by applicant]
US 20220087951A1
· Guy et al.
· 2022
[cited by applicant]
US 20220096397A1
· Wright et al.
· 2022
[cited by applicant]
US 20220168266A1
· Guy et al.
· 2022
[cited by applicant]
US 20220183997A1
· Guy et al.
· 2022
[cited by applicant]
US 20220184000A1
· Guy et al.
· 2022
[cited by applicant]
US 20220202738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220211629A1
· Wilkhu et al.
· 2022
[cited by applicant]
US 20220226257A1
· Guy et al.
· 2022
[cited by applicant]
US 20220233495A1
· Silcock et al.
· 2022
[cited by applicant]
US 20220249396A1
· Guy et al.
· 2022
[cited by applicant]
US 20220257529A1
· Guy et al.
· 2022
[cited by applicant]
US 20220265573A1
· Guy et al.
· 2022
[cited by applicant]
US 20220362149A1
· Shah
· 2022
[cited by applicant]
US 20220378714A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378715A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220387347A1
· Whalley et al.
· 2022
[cited by applicant]
US 20220395471A1
· Guy et al.
· 2022
[cited by applicant]
US 20230032502A1
· Guy et al.
· 2023
[cited by applicant]
US 20230038423A1
· Silcock et al.
· 2023
[cited by applicant]
US 20230068885A1
· Guy et al.
· 2023
[cited by applicant]
US 20230143812A1
· Knappertz et al.
· 2023
[cited by applicant]
US 20230235825A1
· Thompson et al.
· 2023
[cited by applicant]
US 20230277560A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277561A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277562A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277563A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285419A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285420A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285421A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285422A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285423A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285424A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285426A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285428A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230301934A1
· Whalley et al.
· 2023
[cited by applicant]
US 20230301936A1
· Guy et al.
· 2023
[cited by applicant]
US 20230310464A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372367A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372368A1
· Checketts et al.
· 2023
[cited by applicant]
US 20240016819A1
· Craig et al.
· 2024
[cited by applicant]
US 20240025858A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240033229A1
· Guy et al.
· 2024
[cited by applicant]
US 20240033272A1
· Checketts et al.
· 2024
[cited by applicant]
US 20240050452A1
· Craig et al.
· 2024
[cited by applicant]
US 20240091241A1
· Guy et al.
· 2024
[cited by applicant]
US 20240130981A1
· Wilkhu et al.
· 2024
[cited by applicant]
US 20240131041A1
· Tse et al.
· 2024
[cited by applicant]
US 20240165048A1
· Guy et al.
· 2024
[cited by applicant]
US 20240207220A1
· Guy et al.
· 2024
[cited by applicant]
US 20240215910A1
· Tse et al.
· 2024
[cited by applicant]
US 20240226032A9
· Wilkhu et al.
· 2024
[cited by applicant]
US 20240226123A9
· Tse et al.
· 2024
[cited by applicant]
US 20240238218A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254066A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254072A1
· Silcock et al.
· 2024
[cited by applicant]
EP 3061450A1
· 2016
[cited by applicant]
WO WO0195899A2
· 2001
[cited by applicant]
WO WO2014062965A1
· 2014
[cited by applicant]
WO WO2015193667A1
· 2015
[cited by applicant]
WO WO2015193668A1
· 2015
[cited by applicant]
WO WO2016094810A2
· 2016
[cited by applicant]
WO WO2016135308A1
· 2016
[cited by applicant]
WO WO2016203239A1
· 2016
[cited by applicant]
WO WO2018061007A1
· 2018
[cited by applicant]
WO WO2018205022A1
· 2018
[cited by applicant]
Namba K, Yamamoto H, Sasaki I, Mori K, Imagawa H, Nishizawa M. Hg (OTf) 2-catalyzed arylene cyclization. Organic Letters. May 1, 2008;10(9):1767-70. (Year: 2008).
[cited by examiner]
Carral-Menoyo A, Misol A, Gómez-Redondo M, Sotomayor N, Lete E. Palladium (II)-Catalyzed Intramolecular C—H Alkenylation for the Synthesis of Chromanes. The Journal of Organic Chemistry. Jan. 14, 2019;84(4):2048-60. (Ye…
[cited by examiner]
Schafroth MA, Rummelt SM, Sarlah D, Carreira EM. Enantioselective Iridium-catalyzed allylic cyclizations. Organic letters. Jun. 16, 2017;19(12):3235-8. (Year: 2017).
[cited by examiner]
Huffman JW, Yu S. Synthesis of a tetracyclic, conformationally constrained analogue of Δ8-THC. Bioorganic & medicinal chemistry. Dec. 1, 1998;6(12):2281-8. (Year: 1998).
[cited by examiner]
Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. New England Journal of Medicine. Sep. 10, 2015;373(11):1048-58. (Year: 2015).
[cited by examiner]
Kimball, A. W. et al., “Chemical Protection against Ionizing Radiation,” Radiation Research, 7:1-12 (1957).
[cited by applicant]
Litchfield, J. T. & Wilcoxon, F., “A simplified method of evaluating dose-effect experiments,” Fed Proc. Mar. 1948; 7(1 Pt 1):240, 15 pages.
[cited by applicant]
Loscher, W. et al., “The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models,” Epilepsy Res. Mar. 1991; 8(2):79-94. doi…
[cited by applicant]
Epidiolex® (cannabidiol) oral solution, CV, Prescribing Information, 2018, 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
[cited by applicant]
Harvey, D. J., “Characterization of the butyl homologues of Δ1-tetrahydrocannabinol, cannabinol and cannabidiol in samples of cannabis by combined gas chromatography and mass spectrometry,” J. Pharm. Pharmac., 28:280-28…
[cited by applicant]
Hill, T. D. M. et al., “Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism,” British Journal of Pharmacology, 170:679-692 (2013).
[cited by applicant]
Morales, P. et al., “An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol,” Frontiers in Pharmacology, 8:422 (2017); doi:10.3389/fphar.2017.00422, 18 pages.
[cited by applicant]
Pertwee, “The Pharmacology and Therapeutic Potential of Cannabidiol,” Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004).
[cited by applicant]
Vree et al., “Identification of hashish of tetrahydrocannabinol, cannabidiol and cannabinol analogues with a methyl side-chain,” J. Pharm. Pharmac. 24:7-12 (1972).
[cited by applicant]
U.S. Appl. No. 15/640,033, filed Jun. 30, 2017.
[cited by applicant]
U.S. Appl. No. 16/467,639, filed Jun. 7, 2019.
[cited by applicant]
U.S. Appl. No. 16/768,241, filed May 29, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,350, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,354, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,357, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 17/050,956, filed Oct. 27, 2020.
[cited by applicant]
U.S. Appl. No. 16/935,005, filed Jul. 21, 2020.
[cited by applicant]
U.S. Appl. No. 17/296,066, filed May 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/296,076, filed May 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/424,682, filed Jul. 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/426,442, filed Jul. 28, 2021.
[cited by applicant]
U.S. Appl. No. 17/406,401, filed Aug. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/435,892, filed Sep. 2, 2021.
[cited by applicant]
U.S. Appl. No. 17/470,382, filed Sep. 9, 2021.
[cited by applicant]
U.S. Appl. No. 17/472,000, filed Sep. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/472,016, filed Sep. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/548,232, filed Dec. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/606,370, filed Oct. 25, 2021.
[cited by applicant]
U.S. Appl. No. 17/611,824, filed Nov. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/529,005, filed Nov. 17, 2021.
[cited by applicant]
U.S. Appl. No. 17/615,422, filed Nov. 30, 2021.
[cited by applicant]
U.S. Appl. No. 17/552,487, filed Dec. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/631,069, filed Jan. 28, 2022.
[cited by applicant]
U.S. Appl. No. 17/638,629, filed Feb. 25, 2022.
[cited by applicant]
U.S. Appl. No. 17/689,607, filed Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/689,245, filed Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/744,224, filed May 13, 2022.
[cited by applicant]
U.S. Appl. No. 17/705,443, filed Mar. 28, 2022.
[cited by applicant]
U.S. Appl. No. 17/680,048, filed Apr. 11, 2022.
[cited by applicant]
U.S. Appl. No. 17/770,435, filed Apr. 20, 2022.
[cited by applicant]
U.S. Appl. No. 17/770,436, filed Apr. 20, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,184, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,190, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,195, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,183, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,734, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,677, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,681, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/786,949, filed Jun. 17, 2022.
[cited by applicant]
U.S. Appl. No. 17/853,367, filed Jun. 29, 2022.
[cited by applicant]
U.S. Appl. No. 17/816,349, filed Jul. 29, 2022.
[cited by applicant]
U.S. Appl. No. 17/819,046, filed Aug. 11, 2022.
[cited by applicant]
U.S. Appl. No. 18/005,838, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,841, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,845, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,843, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,847, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,848, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,851, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,852, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,853, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,959, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,960, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,961, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,125, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,127, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,129, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18,006,131, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18,006,133, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,121, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/161,603, filed Jan. 30, 2023.
[cited by applicant]
U.S. Appl. No. 18/170,235, filed Feb. 16, 2023.
[cited by applicant]
U.S. Appl. No. 18/043,810, filed Mar. 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/044,941, filed Mar. 10, 2023.
[cited by applicant]
U.S. Appl. No. 18/245,856, filed Mar. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/186,792, filed Mar. 20, 2023.
[cited by applicant]
Cited By (1)